Literature DB >> 2546760

The expression and purification of human rhinovirus protease 3C.

J A Knott1, D C Orr, D S Montgomery, C A Sullivan, A Weston.   

Abstract

Human rhinovirus type 14 protease 3C was expressed as a soluble and active protein in Escherichia coli. The protease was purified by a cationic-exchange step followed by gel filtration on a TSK 3000 column. The final yield of purified protease was in the range 0.5-1.0 mg/l culture grown to A550 = 1.0. Sequence analysis revealed that greater than 90% of the N-terminal residues were methionine. The enzyme activity of the purified protease was measured by cleavage of a synthetic peptide representing a predicted Gln/Gly viral polyprotein cleavage site. A mutant protease (Cys146----Ser) was produced and purified in the same way. The yield of mutant protease 3C was approximately 150 micrograms/l from a culture grown to A550 = 1.0. This mutant protease 3C did not cleave the synthetic peptide substrate.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2546760     DOI: 10.1111/j.1432-1033.1989.tb14862.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  4 in total

1.  Identification of active-site residues in protease 3C of hepatitis A virus by site-directed mutagenesis.

Authors:  R Gosert; G Dollenmaier; M Weitz
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

2.  Mengo virus 3C proteinase: recombinant expression, intergenus substrate cleavage and localization in vivo.

Authors:  D J Hall; A C Palmenberg
Journal:  Virus Genes       Date:  1996       Impact factor: 2.332

3.  A simple and efficient expression and purification system using two newly constructed vectors.

Authors:  Huanting Liu; James H Naismith
Journal:  Protein Expr Purif       Date:  2008-09-20       Impact factor: 1.650

Review 4.  The human rhinovirus: human-pathological impact, mechanisms of antirhinoviral agents, and strategies for their discovery.

Authors:  Judith M Rollinger; Michaela Schmidtke
Journal:  Med Res Rev       Date:  2011-01       Impact factor: 12.944

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.